<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01121380</url>
  </required_header>
  <id_info>
    <org_study_id>BL-1021.01</org_study_id>
    <nct_id>NCT01121380</nct_id>
  </id_info>
  <brief_title>A Study Intended to Evaluate Safety, Tolerability and Pharmacokinetics (PK) Parameters of BL-1021</brief_title>
  <official_title>A First-in-Human, Randomized, Double-Blind, Placebo Controlled, Single-Center Combined Single-Ascending Dose and Multiple-Ascending Dose, Parallel Groups, Study to Assess Safety, Tolerability and Pharmacokinetics of BL-1021 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioLineRx, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioLineRx, Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety, tolerability and pharmacokinetics of BL-1021&#xD;
      in healthy volunteers. Subsequent clinical studies will be designed to test the safety and&#xD;
      efficacy of BL-1021 in patients with neuropathic pain based on data obtained from the&#xD;
      proposal trial described below.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 32 subjects in the single-ascending phase and 24 subjects in the multiple&#xD;
      ascending phase, who have provided a written informed consent and comply with&#xD;
      inclusion/exclusion criteria will participate in the study in 4 different cohorts in the&#xD;
      first phase (cohorts A, B, C and D) and 3 different cohorts in the second phase (cohorts E, F&#xD;
      and G), each consisting of 8 subjects.&#xD;
&#xD;
      First part dosing:&#xD;
&#xD;
      Cohort A - 10 mg Cohort B - 20 mg Cohort C - 30 mg Cohort D - 40 mg&#xD;
&#xD;
      Second part dosing:&#xD;
&#xD;
      Cohort E - X mg (X shall be determined using the results of the 1st part) Cohort F - 2X mg&#xD;
      Cohort G - 4X mg&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor strategy change&#xD;
  </why_stopped>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Part 1 and 2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in vital signs</measure>
    <time_frame>Part 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in laboratory parameters</measure>
    <time_frame>Part 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax, Tmax, AUCT, AUCI, kel, TÂ½</measure>
    <time_frame>Part 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose linearity of PK parameters</measure>
    <time_frame>part 1 and 2</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <condition>Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort A - 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B - 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C - 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D - 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort E - X mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2, multiple dose. X shall be determined using the results of part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort F - 2X mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2, multiple dose. X shall be determined using the results of part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort G - 4X mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2, multiple dose. X shall be determined using the results of part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In each cohort there is a placebo arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BL-1021</intervention_name>
    <description>BL-1021 is an orally available NCE which contains an elongated aliphatic side-chain.&#xD;
Dosage:&#xD;
Part 1 - Single Dose: 1 dose on Day 1, dosage will be 10, 20, 40 &amp; 80 mg according the cohort Part 2 - Multiple Dosing: up to 7 once-daily administrations. Dosage will be determined according the first part results.</description>
    <arm_group_label>Cohort A - 10 mg</arm_group_label>
    <arm_group_label>Cohort B - 20 mg</arm_group_label>
    <arm_group_label>Cohort C - 40 mg</arm_group_label>
    <arm_group_label>Cohort D - 80 mg</arm_group_label>
    <arm_group_label>Cohort E - X mg</arm_group_label>
    <arm_group_label>Cohort F - 2X mg</arm_group_label>
    <arm_group_label>Cohort G - 4X mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1021</intervention_name>
    <description>1021</description>
    <arm_group_label>Cohort A - 10 mg</arm_group_label>
    <arm_group_label>Cohort B - 20 mg</arm_group_label>
    <arm_group_label>Cohort C - 40 mg</arm_group_label>
    <arm_group_label>Cohort D - 80 mg</arm_group_label>
    <arm_group_label>Cohort E - X mg</arm_group_label>
    <arm_group_label>Cohort F - 2X mg</arm_group_label>
    <arm_group_label>Cohort G - 4X mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        The inclusion criteria for both parts 1 and 2 of the study are:&#xD;
&#xD;
          -  Ability to provide written informed consent&#xD;
&#xD;
          -  Healthy male between 18 and 45 years of age, inclusive&#xD;
&#xD;
          -  BMI of 18-30, inclusive&#xD;
&#xD;
          -  Negative urinary drugs of abuse screen within 21 days of start of study&#xD;
&#xD;
          -  No significant abnormal blood hematology and biochemistry tests according to the&#xD;
             opinion of the principal investigator&#xD;
&#xD;
          -  Only subjects with a known (pre-study) CYP2D6 genotype will be enrolled.&#xD;
&#xD;
          -  No concomitant medications (prescription, OTC, vitamins, dietary supplements) within 7&#xD;
             days prior to administration of study medication&#xD;
&#xD;
          -  Non-smoking (by declaration) for a period of at least 6 months prior to enrolment&#xD;
&#xD;
          -  Ability to adhere to the visit schedule and protocol requirements and be available to&#xD;
             complete the study&#xD;
&#xD;
          -  No significant abnormalities in physical examination&#xD;
&#xD;
        Exclusion criteria for both parts 1 and 2 of the study are:&#xD;
&#xD;
          -  Evidence or history of significant concomitant disease (including mental, CNS-related,&#xD;
             renal, hepatic, cardiovascular, pulmonary disease, or other)&#xD;
&#xD;
          -  Prior or current history of cancer, except for cured basal cell carcinoma of the skin&#xD;
&#xD;
          -  History of significant abnormalities in ECG, including QT prolongation&#xD;
&#xD;
          -  History of significant neurological, renal, cardiovascular, respiratory (asthma),&#xD;
             endocrinological, gastrointestinal, hematopoietic disease, neoplasm (especially&#xD;
             melanoma), or any other clinically significant medical disorder, which in the&#xD;
             Investigator's judgment contraindicate administration of the study medications&#xD;
&#xD;
          -  Use of another investigational medication/treatment in the past 30 days&#xD;
&#xD;
          -  History of drug or alcohol abuse&#xD;
&#xD;
          -  Significant abnormalities in screening physical examination&#xD;
&#xD;
          -  Significant abnormalities in clinical laboratory parameters (hematology, biochemistry,&#xD;
             serology, urinalysis)&#xD;
&#xD;
          -  History of gastrointestinal disorder likely to influence drug absorption&#xD;
&#xD;
          -  Consumption of Serotonin-Norepinephrine Reuptake Inhibitors (SNRI's), selective&#xD;
             serotonin reuptake inhibitors (SSRI's), tricyclic/tetracyclic antidepressants within&#xD;
             90 days prior to Day 0&#xD;
&#xD;
          -  Consumption of drugs that may potentially inhibit or induce liver cytochrome P450&#xD;
             activity within 3 weeks prior to Day 0&#xD;
&#xD;
          -  Subjects who are either extensive-extensive metabolizers (i.e. carriers of multiple&#xD;
             CYP2D6 gene copies) or poor metabolizers of CYP 2D6 will be excluded.&#xD;
&#xD;
          -  Any acute medical situation (e.g. acute infection) within 48 hours of Day 0, which is&#xD;
             considered of significance by the Principal Investigator&#xD;
&#xD;
          -  Unusual diet&#xD;
&#xD;
          -  Sero-positive HIV, HBSAg or HCV&#xD;
&#xD;
          -  Donation of 450ml or more blood within the previous 12 weeks&#xD;
&#xD;
          -  Probability of undertaking intense physical activity throughout the study duration&#xD;
             (Single Dose: Day 0 - Day 8, Multiple Dose: Day 0 - Day 14)&#xD;
&#xD;
          -  Any condition, which in the opinion of the Principal Investigator would place the&#xD;
             subject at risk or influence the conduct of the study or interpretation of results&#xD;
&#xD;
          -  Inability to communicate well with the Investigator (i.e., language problem, poor&#xD;
             mental development or impaired cerebral function)&#xD;
&#xD;
          -  Subjects who, in the judgment of the investigators, are likely to be non-compliant or&#xD;
             uncooperative or unwilling to sign a consent form&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yotam Nisemblat</last_name>
    <role>Study Director</role>
    <affiliation>BioLineRx, Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yoseph Caraco, Prof, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Clinical Research Center (HCRC)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hadassah Clinical Research Center (HCRC)</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>May 10, 2010</study_first_submitted>
  <study_first_submitted_qc>May 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2010</study_first_posted>
  <last_update_submitted>March 12, 2014</last_update_submitted>
  <last_update_submitted_qc>March 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy</keyword>
  <keyword>Volunteers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

